ClearPoint Neuro (NASDAQ:CLPT) CEO Sells $322,400.00 in Stock

ClearPoint Neuro, Inc. (NASDAQ:CLPT) CEO Joseph Burnett sold 20,000 shares of the firm’s stock in a transaction dated Friday, January 9th. The stock was sold at an average price of $16.12, for a total transaction of $322,400.00. Following the sale, the chief executive officer owned 11,565 shares of the company’s stock, valued at $186,427.80. This trade represents a 63.36% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

ClearPoint Neuro Stock Performance

CLPT traded down $1.18 during midday trading on Tuesday, reaching $14.47. The company had a trading volume of 1,439,908 shares, compared to its average volume of 797,354. The company has a debt-to-equity ratio of 1.84, a quick ratio of 5.56 and a current ratio of 6.37. The stock has a market cap of $411.24 million, a PE ratio of -17.23 and a beta of 0.91. ClearPoint Neuro, Inc. has a 12-month low of $9.76 and a 12-month high of $30.10. The business has a 50-day moving average price of $14.52 and a two-hundred day moving average price of $15.03.

ClearPoint Neuro (NASDAQ:CLPT) last issued its quarterly earnings results on Thursday, November 6th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.01). The company had revenue of $5.36 million for the quarter, compared to analysts’ expectations of $9.60 million. ClearPoint Neuro had a negative return on equity of 114.28% and a negative net margin of 67.40%. On average, sell-side analysts expect that ClearPoint Neuro, Inc. will post -0.66 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on CLPT shares. Wall Street Zen downgraded ClearPoint Neuro from a “hold” rating to a “sell” rating in a research note on Saturday, November 15th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of ClearPoint Neuro in a report on Wednesday, October 8th. Three analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $19.67.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in CLPT. Millennium Management LLC increased its position in shares of ClearPoint Neuro by 156.3% during the first quarter. Millennium Management LLC now owns 741,193 shares of the company’s stock valued at $8,813,000 after buying an additional 452,043 shares during the period. Geode Capital Management LLC grew its stake in ClearPoint Neuro by 107.3% during the second quarter. Geode Capital Management LLC now owns 624,800 shares of the company’s stock valued at $7,461,000 after acquiring an additional 323,429 shares in the last quarter. Two Sigma Investments LP increased its holdings in ClearPoint Neuro by 1,316.1% during the 3rd quarter. Two Sigma Investments LP now owns 310,526 shares of the company’s stock worth $6,766,000 after acquiring an additional 288,598 shares during the period. Boone Capital Management LLC bought a new position in ClearPoint Neuro in the 3rd quarter valued at $6,186,000. Finally, UBS Group AG grew its position in shares of ClearPoint Neuro by 132.1% during the 3rd quarter. UBS Group AG now owns 360,705 shares of the company’s stock valued at $7,860,000 after purchasing an additional 205,295 shares in the last quarter. Hedge funds and other institutional investors own 30.08% of the company’s stock.

ClearPoint Neuro Company Profile

ClearPoint Neuro, Inc is a medical technology company specializing in the development and commercialization of an MRI-guided therapy platform for minimally invasive neurosurgical procedures. Headquartered in Cambridge, Massachusetts, the company’s flagship ClearPoint® SmartFrame™ system enables surgeons to perform accurate and efficient intracranial interventions by providing real-time magnetic resonance imaging feedback. This technology is designed to improve patient safety and outcomes in treatments ranging from deep brain stimulation electrode placement to laser ablation of epileptic foci and brain tumors.

The ClearPoint System integrates hardware, software and imaging capabilities to guide instruments through the brain with submillimeter precision.